Dare Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Dare Bioscience, Inc. (DARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.40% for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2017-11-13
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-09-30 was 1.30%, a 23.98% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-03-31 was 1.90%, a 12.43% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2015-09-30 was 1.71%, a 14.50% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2015-06-30 was 2.00%, a 0.00% change year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 2.32%, a 14.85% increase from fiscal 2015.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.02%, a 1.00% increase from fiscal 2014.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2014 was 2.00%, a 4.17% increase from fiscal 2013.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.92%, a 71.43% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|---|
| 2017-09-30 | 2.40% 10-Q · filed 2017-11-13 | |||||
| 2016-12-31 | 2.32% 10-K/A · filed 2017-06-13 | |||||
| 2016-09-30 | 1.30% 10-Q · filed 2016-11-03 | 1.90% 10-Q · filed 2016-11-03 | ||||
| 2016-06-30 | 1.90% 10-Q · filed 2017-08-14 | |||||
| 2016-03-31 | 1.90% 10-Q · filed 2017-05-12 | 1.89% 10-Q · filed 2016-05-02 | ||||
| 2015-12-31 | 2.02% 10-K/A · filed 2017-06-13 | |||||
| 2015-09-30 | 1.71% 10-Q · filed 2015-11-16 | 2.00% 10-Q · filed 2016-11-03 | 2.02% 10-Q · filed 2015-11-16 | |||
| 2015-06-30 | 2.00% 10-Q · filed 2016-08-04 | 2.00% 10-Q · filed 2016-08-04 | ||||
| 2015-03-31 | 1.69% 10-Q · filed 2016-05-02 | |||||
| 2014-12-31 | 2.00% 10-K/A · filed 2017-06-13 | |||||
| 2014-09-30 | 2.00% 10-Q · filed 2015-11-16 | 2.00% 10-Q · filed 2015-11-16 | ||||
| 2014-06-30 | 2.00% 10-Q · filed 2015-08-06 | 1.97% 10-Q · filed 2014-08-12 | 2.00% 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | 2.00% 10-Q · filed 2015-05-06 | |||||
| 2013-12-31 | 1.92% 10-K · filed 2016-03-10 | |||||
| 2012-12-31 | 1.12% 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |